# Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

> **NCT06191315** · PHASE3 · RECRUITING · sponsor: **Sanofi** · enrollment: 90 (estimated)

## Conditions studied

- Wheezing
- Asthma

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06191315
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-03
- **Primary completion:** 2028-12-21
- **Final completion:** 2028-12-21
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06191315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06191315, "Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06191315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*